Halozyme Therapeutics — Aug 6, 2026 release

For the full year 2026, the Company expects: • Total revenue of $1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API. • Revenue from royalties of $1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025. • Adjusted EBITDA of $1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025, including new Hypercon™ and Surf Bio investments of approximately $60 million. • Non-GAAP diluted earnings per share of $8.65 to $9.00, representing growth of 108% to 117% over 2025. The Company’s earnings per share guidance includes new Hypercon™ and Surf Bio investments of approximately $60 million and does not consider the impact of potential future share repurchases. Table 1. 2026 Financial Guidance Previous Guidance Range New Guidance Range Total Revenue $1.710 to $1.810 billion $1.835 to $1.910 billion Royalty Revenue $1.130 to $1.170 billion $1.220 to $1.245 billion Adjusted EBITDA 1 $1.125 to $1.205 billion $1.225 to $1.280 billion Non-GAAP Diluted EPS 1 $7.75 to $8.25 $8.65 to $9.00 1     EBITDA, Adjusted EBITDA and Non-GAAP Diluted EPS are Non-GAAP financial measures. See “Note Regarding Use of Non-GAAP Financial Measures” below for an explanation of these measures. Reconciliations between GAAP reported and Non-GAAP financial information for actual results are provided at the end of this earnings release. Webcast and Conference